Kestra's ASSURE wearable defibrillator achieves 100% conversion in largest real-world study

KESTRA MEDICAL TECHNOLOGIES, LTD.

21,612-patient ACE-PAS trial met primary effectiveness endpoint: 100% successful conversion for VT/VF events.
Inappropriate-shock rate of 0.0065 per patient-month, below prespecified safety performance goal.
94% of patients experienced no false positive shock alarms; median wear time >23 hours per day.
2.6% of patients had at least one life-threatening VT/VF event, highlighting early risk.
Results presented as late-breaking science at AHA Scientific Sessions 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.